B

한국유니온제약

080720KOSDAQ의약품 제조업

59.0 / 100

Reference Date: 2026-04-13

Financial Score26.5 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Korea Union Pharmaceutical focuses on manufacturing and selling specialty pharmaceuticals, exporting finished drugs, and providing CMO (contract manufacturing) services. The company specializes in antibiotics, cardiovascular, and musculoskeletal products, leveraging its GMP facilities and R&D efforts to enhance profitability. It has expanded exports to regions such as the Middle East, Southeast Asia, and South America, and is further expanding its CMO business and product portfolio through a newly completed factory.

Number of Employees

123people

Average Salary

39.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 14.804.0Point
PBR
Industry Average 1.043.5Point
ROE
419.43Industry Average 4.427.0Point

94.9x industry avg (excellent)

Debt Ratio
-21.02Industry Average 11.988.0Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼23.9% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼92.6% (2-year basis)

ROE Trend
4.0 / 4

Avg ROE 88.4% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position4.0Point

52w mid range (50%)

Current 2,725Won52-week high 2,72552-week low 2,725
1-month return3.0Point

1m 0% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

11 totalPositive 0Neutral 11Negative 0
  • Neutral기타경영사항(자율공시) (상장폐지결정 등 효력정지 가처분 신청)2026-04-06
  • Neutral주권매매거래정지 (투자자 보호)2026-04-06
  • Neutral기타시장안내 (정리매매 보류 관련)2026-04-06
  • Neutral기타시장안내 (코스닥시장위원회 개최 결과 및 상장폐지 결정 안내)2026-04-03
  • Neutral주권매매거래정지해제 (상장폐지에 따른 정리매매 개시)2026-04-03